

**Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting**

**February 6, 2019**

**Location: Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa, 50315  
Rooms 128, 129, 130, 131**

**Time: 9:30 a.m. – 1:30 p.m.**

**Tentative Agenda**

1. Welcome & Introductions
  - a) Commission Members and Staff
2. Commission Business
  - a) Approval of the Minutes
  - b) DHS Recommendation Letter – November 2018
  - c) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
  - a) United Healthcare Community Plan
  - b) Amerigroup
6. Public Comment\* (See Speaker Conflict of Interest Disclosure Form)
7. H.R. 6 SUPPORT for Patients and Communities Act - Review Sec. 1004
8. ProDUR Edits
  - a) Concurrent use of Opioids and Benzodiazepines – Initial Review
  - b) Concurrent use of Opioids and Antipsychotics – Initial Review
  - c) Duplicate Antipsychotics in Adults – Second Review
  - d) CNS Stimulants and Atomoxetine Concurrent Therapy ProDUR Edit - Second Review
  - e) CNS Stimulants and Atomoxetine Age Edit - Second Review
9. Break (10 minutes)
10. Prior Authorization
  - a) Sodium Oxybate (Xyrem) – Initial Review

- b) Buprenorphine/Naloxone – Initial Review
- c) Short-Acting Opioids – Initial Review
- d) Long-Acting Opioids – Initial Review
- e) Kalydeco (Ivacaftor) – Second Review
- f) Orkambi (Lumacaftor/Ivacaftor) – Second Review
- g) Hematopoietics/Chronic ITP (Thrombopoietin Receptor Agonists) – Second Review
- h) Elagolix (Orilissa) – Second Review
- i) Oral Constipation Agents – Second Review
- j) Desmopressin Acetate Nasal Spray (Noctiva) – Second Review

11. Miscellaneous

- a) DUR Digest Vol. 31, No. 2 – Initial Review
- b) MedWatch
- c) Articles of Interest

12. Adjournment

\*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**Next Meeting  
May 1, 2019**

**\*\*\*Location to be Determined\*\*\***